There is a lack of data on the use of short-term androgen deprivation therapy (stADT) in combination with high-dose radiotherapy (RT) versus RT alone for patients with localized prostate cancer (PCa). The recent GETUG 14 randomized phase III trial has analyzed stADT plus RT to gain more insight on these treatments. Previous research has demonstrated the benefit of stADT for 4 months before and during RT for localized, intermediate-risk PCa. GETUG 14 recruited 376 patients with both intermediate- and high-risk PCa, randomizing them to receive either RT (n=191) or stADT plus RT (n=179). ...
Localized Prostate Cancer
Advertisement
Latest News
Dr. Greenstein shares insights on the overall survival benefit of apalutamide over enzalutamide in a recent real-world study.
Patients were guided through a VR experience to view their specific anatomy in a 3-dimensional space.
Data show that of patients with prostate cancer, Black men face higher incidence and mortality rates than White men.
For the treatment of localized prostate cancer, guidelines typically recommend the addition of ADT to RT in certain patients.
Drs. Stifelman and Ambinder discuss the novel approaches and adoption challenges of single-port and Da Vinci 5 systems.
Dr. Shore discusses treatment-related adverse events associated with apalutamide and ADT.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content based on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
Advertisement
Advertisement
Trending
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.